Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of UB-221 add-on therapy in adults with chronic spontaneous urticaria
CTR20233674Phase 2Active
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ub-221 in chronic idiopathic urticaria (CIU) (4 arms), sponsored by United BioPharma. Primary endpoint: Percentage of patients with HSS7 = 0. Started Dec 2023; status: active.
02
Drugs
ub-221
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20233674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233674.